NCT06493968 Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With PASD Undergoing Cesarean Hysterectomy
| NCT ID | NCT06493968 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Placenta Accreta Spectrum |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2024-07-01 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Objectives: To evaluate the effect of oxytocin in reducing intraoperative blood loss in patients with PAS disorders planned for cesarean hysterectomy.
Eligibility Criteria
Inclusion Criteria: * Pregnancy of singleton living fetus * Previous one or more cesarean sections * Gestational age: \> 32 weeks * The following ultrasound markers such as "loss of clear retroplacental translucency", "myometrial thinning", "abnormal lacunae", "irregular bladder wall", "utero-vesicalhypervascularity". * Preoperative hemoglobin more than 10 gm/dl * Cases with PAS that will undergoing CS Hysterectomy Exclusion Criteria: * Maternal medical disorders e.g.: coagulation defects, cardiac diseases etc.…. * Any known or reported hypersensitivity to the used medication. * All cases with spontaneous placental separation at laparotomy. * All patients undergoing conservative management of PAS. * All cases which necessitate emergency termination.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06493968 clinical trial?
This trial is open to female participants only, aged 20 Years or older, up to 40 Years, studying Placenta Accreta Spectrum. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06493968 currently recruiting?
Yes, NCT06493968 is actively recruiting participants. Contact the research team at Dr_abdallamousa@yahoo.com for enrollment information.
Where is the NCT06493968 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06493968 clinical trial?
NCT06493968 is sponsored by Cairo University. The trial plans to enroll 70 participants.